Mitochondrial dynamics in pulmonary arterial hypertension

Area of Science:

• Cardiology
• Mitochondrial Biology
• Pulmonary Hypertension Research

Background:

• Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease marked by small pulmonary artery obstruction.
• Vascular obstruction in PAH results from excessive cell proliferation, apoptosis resistance, inflammation, thrombosis, and vasoconstriction, leading to right ventricle failure.
• PAH shares mitochondrial abnormalities with cancer, including aerobic glycolysis and mitochondrial fragmentation.

Purpose of the Study:

• To review the etiology of mitochondrial fragmentation in pulmonary arterial hypertension (PAH).
• To explore the therapeutic implications of mitochondrial dynamics in the pulmonary vasculature and right ventricle in PAH.
• To highlight novel therapeutic targets based on mitochondrial abnormalities in PAH.

Main Methods:

• Review of current literature on mitochondrial abnormalities in PAH.
• Analysis of the role of mitochondria as oxygen sensors in pulmonary artery smooth muscle cells (PASMCs).
• Examination of molecular mechanisms driving mitochondrial fragmentation and metabolic shifts in PAH.

Main Results:

• Mitochondrial abnormalities in PAH include epigenetic silencing of SOD2, leading to a pseudo-hypoxic state and HIF-1α activation.
• A metabolic shift to aerobic glycolysis (Warburg effect) is driven by pyruvate dehydrogenase kinase inhibition.
• Altered mitochondrial dynamics involve increased fission (DRP-1) and decreased fusion (MFN2), causing fragmentation.

Conclusions:

• Mitochondrial fragmentation and associated metabolic changes are key pathogenic mechanisms in PAH.
• Targeting mitochondrial dynamics, such as inhibiting DRP-1 or enhancing MFN2, shows therapeutic potential.
• Interventions modulating mitochondrial fission/fusion can reduce proliferation, induce cell cycle arrest, and promote apoptosis in PAH PASMCs, potentially regressing PAH in models.